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Background: Anoikis resistance is one of the abilities acquired along tumor progression. This characteristic is
associated with metastasis development, since tumorigenic cells must survive independently of cell-matrix
interactions in this process. In our laboratory, it was developed a murine melanocyte malignant transformation
model associated with a sustained stressful condition. After subjecting melan-a melanocytes to 1, 2, 3 and 4 cycles
of anchorage impediment, anoikis resistant cells were established and named 1C, 2C, 3C and 4C, respectively. These
cells showed altered morphology and PMA independent cell growth, but were not tumorigenic, corresponding to
pre-malignant cells. After limiting dilution of 4C pre-malignant cells, melanoma cell lines with different
characteristics were obtained. Previous data from our group showed that increased Timp1 expression correlated
with anoikis-resistant phenotype. Timp1 was shown to confer anchorage-independent growth capability to melan-a
melanocytes and render melanoma cells more aggressive when injected into mice. However, the mechanisms
involved in anoikis regulation by Timp1 in tumorigenic cells are not clear yet.
Methods: The β1-integrin and Timp1 expression were evaluated by Western blotting and CD63 protein expression
by flow cytometry using specific antibodies. To analyze the interaction among Timp1, CD63 and β1-integrin,
immunoprecipitation assays were performed, anoikis resistance capability was evaluated in the presence or not of
the PI3-K inhibitors, Wortmannin and LY294002. Relative expression of TIMP1 and CD63 in human metastatic
melanoma cells was analyzed by real time PCR.
Results: Differential association among Timp1, CD63 and β1-integrins was observed in melan-a melanocytes,
4C pre-malignant melanocytes and 4C11- and 4C11+ melanoma cells. Timp1 present in conditioned medium of
melanoma cells rendered melan-a melanocytes anoikis-resistant through PI3-K signaling pathway independently of
Akt activation. In human melanoma cell lines, in which TIMP1 and beta-1 integrin were also found to be interacting,
TIMP1 and CD63 levels together was shown to correlate significantly with colony formation capacity.
Conclusions: Our results show that Timp1 is assembled in a supramolecular complex containing CD63 and
β1-integrins along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway,
independently of Akt phosphorylation. In addition, our data point TIMP1, mainly together with CD63, as a potential
biomarker of melanoma.
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Cutaneous melanoma originates from malignant trans-
formation of melanocytes. As in the case of most cancers,
it is believed that genetic and environmental factors con-
tribute to development of melanoma. Although melanoma
is the less frequent skin cancer (about 4%), it is responsible
for most deaths (approximately 80%) due its high inci-
dence of metastases [1,2]. Cell-extracellular matrix inter-
actions are a key factor for melanocyte homeostasis and
disruption of such interactions has adverse effects on cell
survival, driving a specific type of apoptosis known as
anoikis. This kind of apoptosis following loss of cell an-
chorage is important for development, tissue homeostasis
and several diseases, including cancer [3]. Anoikis has a
particular importance in tumor progression, since the ac-
quisition of an anoikis-resistant phenotype is one of the
critical steps acquired during malignant transformation
[4]. In animal models, anoikis-resistant tumor cells are
associated with high incidence of metastatic lesions
and increased cell survival in blood [5-8]. Furthermore,
this property observed in these cells when cultured
in vitro can be correlated to its oncogenic potential
found in vivo [9].
A previous work of our group showed that the acquisi-
tion of anoikis-resistant phenotype is associated with
melanocyte malignant transformation [10]. Oba-Shinjo
and colleagues (2006) demonstrated that sequential cy-
cles of anchorage blockade resulted in malignant trans-
formation of melan-a murine melanocytes [10]. As
expected for a non-tumorigenic immortalized cell line,
most melan-a cells underwent anoikis when maintained
in suspension. However, small spheroids were observed
after maintaining melan-a cells in suspension for 96
hours. Melan-a cells resistant to anoikis were cultured in
adherent conditions and subjected to further deadhe-
sion cycles. Cell lines were established after subjecting
melan-a melanocytes to 1, 2, 3 and 4 cycles of anchorage
blockade (1C, 2C, 3C and 4C cell lines, respectively).
These cell lines were non-tumorigenic, but showed
morphological changes, increased anoikis-resistant phe-
notype and alterations in the expression of different
molecules [10], being considered pre-malignant cells.
Pre-malignant 4C melanocytes were subjected to a new
cycle of anchorage blockade and the spheroids formed
were submitted to a limiting dilution. All clones, ran-
domly selected, were tumorigenic when subcutaneously
inoculated into syngeneic mice. In this way, different
melanoma cell lines (i.e. 4C11- and 4C11+) were
established and showed differences in pigmentation, ag-
gregation, in vitro and in vivo proliferation and ability to
metastasize [10].
TIMP1 is a member of the family of matrix
metalloproteinase (MMP) inhibitors that is composed of
four members (TIMP1, TIMP2, TIMP3 and TIMP4).As the name suggests, the main function of TIMP1 is to
inhibit extracellular matrix degradation mediated by
MMPs. However, TIMP1 may interact with other pro-
teins and regulate biological processes such as cell
growth, apoptosis and differentiation, independently of
its metalloproteinase inhibitory activity [11-15]. In this
context, CD63, a member of the tetraspanin family, was
first identified as an antigen associated with early stages
of human melanoma and as a binding partner of TIMP1
on the cell surface [15]. Jung and coworkers [15] showed
a correlation between the expression of TIMP1 and the
level of active β1-integrin on the surface of epithelial
breast cells, independent of cell adhesion, and showed
interaction among TIMP1, CD63 and β1-integrin. Inhib-
ition of CD63 expression was able to effectively reduce
TIMP1 binding on the cell surface and its co-localization
with β1-integrins. Besides that, β1-integrins activation, sig-
naling survival activation and inhibition of apoptosis me-
diated by TIMP1 was abrogated. The mammals’ integrin
family contains 18 α-subunits and eight β-subunits that
form 24 distinct receptors with specific tissue distribution
that appear to have specific and non-redundant functions
as shown by their specificity for ECM ligands and knock-
out mouse phenotypes [16]. The primary function of
integrin family is to mediate cell-cell and cell-matrix adhe-
sion. Furthermore, the binding of ECM components to
integrins leads to the recruitment of numerous adaptor
and signaling proteins to the cytoplasmic tails of the integ-
rin β-subunits, forming adhesion protein complexes that
initiate signaling cascades promoting cell polarity, motility,
differentiation, proliferation and survival [16]. β1-integrins
are expressed in a wide variety of tissues and different cell
types throughout the body. They are critical in the induc-
tion and maintenance of cell differentiation and are in-
volved in various physiological functions and in tissue
homeostasis [16].
Previously, we reported increased Timp1 expression
along melanoma genesis and a tight correlation between
Timp1 expression and its promoter methylation during
melanocytes malignant transformation [17]. It was dem-
onstrated that Timp1 confers resistance to anoikis, since
melanocytes overexpressing Timp1 become able to resist
to anoikis and form colonies in soft-agar. Moreover, mel-
anoma cells overexpressing Timp1 acquire increased
capacity to grow and metastasize in vivo [17]. However,
the signaling pathway induced by Timp1 to protect mel-
anoma cells from apoptosis is still unknown.
The phosphoinositide 3-kinase (PI3K) signaling path-
way activation regulates fundamental cellular func-
tions such as transcription, growth, differentiation and
survival, mostly through AKT phosphorylation [18].
PI3K/AKT signaling is associated with the disruption
in the balance between cell proliferation and apop-
tosis, and has been related with the development of
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mellitus [18].
In this work, we have shown for the first time the as-
sembly of a supramolecular complex containing Timp1,
CD63 and β1-integrins at the cell surface in melanoma
cells, and its involvement in the acquisition of an
anoikis-resistant phenotype through PI3K signaling
pathway independently of Akt activation. In addition,
our data points TIMP1 as a biomarker of human
melanoma.
Material and methods
Cell culture
The non-tumorigenic melan-a melanocyte lineage [19]
was cultured at 37°C in humidified 95% air-5% CO2 in
RPMI pH 6.9 supplemented with 5% fetal bovine serum
(Invitrogen, Scotland, UK), 200 nM 12-phorbol-13-myr-
istate acetate (PMA; Calbiochem, Darmstadt, Germany),
100 U/ml penicillin, and 100 U/ml streptomycin
(Invitrogen, Grand Island, NY). PMA activates protein
kinase C, and is required for melanocytes to survival and
proliferate in culture [19]. Pre-malignant 4C melanocyte
lineage, non-metastatic 4C11- and metastatic 4C11+
melanoma cell lines were cultured as melan-a cells, but
in the absence of PMA, since they lost the requirement
of this factor to grow. Stably Timp1-overexpressing
melan-a (MaT1S) and the control MaGFP were cultured
in the same conditions described above in the presence
of PMA. The plasmid construction and transfection was
previously described [17]. Primary human melanocytes
MP#2, kindly provided by Dr. Silvya Stuchi Maria-Engler
(Faculdade de Ciências Farmacêuticas, Universidade de
São Paulo), was cultured at 37°C in humidified 95% air-5
% CO2 in Cascade growth medium 254 (Gibco, Grand
Island, NY) supplemented with 200 μM CaCl2 and 1%
HGMS (human growth melanocyte supplement). The
patient-derived metastatic melanoma cells Mel2, Mel3,
Mel4, Mel11, Mel14, Mel21, Mel25, Mel28 and Mel33
kindly provided by Dr. Débora C.P. Silva (Ludwig Insti-
tute for Cancer Research, São Paulo), were cultured at
37°C in humidified 95% air-5% CO2 in RPMI pH 7.2
supplemented with 15% fetal bovine serum (Invitrogen,
Scotland, UK), 1 mM sodium piruvate, 2 mM L-
glutamine and antibiotics (Gibco, Grand Island, NY).
mRNA expression analysis
RNA was isolated from cell monolayers (MP#2, Mel2,
Mel3, Mel11, Mel14, Mel21, Mel25, Mel33, Melan-a,
4C, 4C11- and 4C11+) using TRIzolW (Invitrogen, Carls-
bad, CA). cDNA was prepared from 1 μg of RNA using
random hexamer primers and OligodT (Superscript III
first-strand synthesis system for RT-PCR, Invitrogen).
For TIMP1 and CD63 mRNA expression analysis, quan-
titative real-time PCR were performed using a CorbettRotor-Gene 6000 detection systemW with a Fast Rotor-
Gene SYBR Green PCR Master MixW (Qiagen,
Dusseldorf, Germany). Specific primers were used as fol-
lows: human TIMP1 (sense: 5’ ATG TTA CTG TGG
GCT GTG G 3’, antisense: 5’ CGA CAA AAG CAA
TTC CAA GGG 3’), human CD63 (sense: 5’ CCC TTG
GAA TTG CTT TTG TCG 3’, antisense: 5’ CGT AGC
CAC TTC TGA TAC TCT TC 3’), human GAPDH
(sense: 5’ GTC TTC CCC TCC ATC GTG 3’, antisense:
5’ GTA CTT CAG GGT GAG GAT GC 3’), mouse
timp1 (sense: 5’ GCT AAA AGG ATT CAA GGC 3’,
antisense: 5’ GCA CAA GCC TAG ATT CCG 3’), and
mouse gapdh (sense: 5’ CCA TGG AGA AGG CTG
GGG 3’ antisense: 5’ CAA AGT GTC ATG GAT GAC
A 5’).
Western Blotting
Subconfluent cell cultures were trypsinized, washed with
PBS and membrane-enriched protein extracts were pre-
pared using cold lysis buffer (1% Triton X-100 in 150
mM NaCl and 50 mM Tris pH 7.4, containing 5 mM
EDTA, CHAPS 1%, 2 g/mL aprotinin and 1 mM PMSF),
kept for 15 minutes on ice, followed by centrifugation at
10.000 rpm for 15 minutes at 4°C. Alternatively, MaT1S
and MaGFP cells submitted for 1 h (D1h), 3 h (D3h), 5
h (D5h) and 24 h (D24h) were washed and cytoplasmic
protein extracts were carried out using cold lysis buffer
(0.5% NP40 in 100 mM NaCl and 50 mM Tris pH7.4,
containing 50 mM NaF, 1 mM NaVO4, 2 g/mL aprotinin
and 1 mM PMSF), kept for 15 minutes on ice, followed
by centrifugation at 10.000 rpm for 15 minutes at 4°C.
The supernatant was collected and protein concentra-
tion was measured by Bio-Rad protein assay dye reagent
concentrate (Bio-Rad, Hercules, CA). Equivalent
amounts of protein (50 μg) were denaturated in SDS
sample buffer (240 mM Tris–HCl pH 6.8, 0.8% SDS, 200
mM beta- mercaptoethanol, 40% glycerol and 0.02%
bromophenol blue) for 5 minutes, then separated
by electrophoresis in SDS-polyacrylamide gels and
transferred to a polyvinylidene difluoride membrane
(Amersham, Piscataway, NJ). After protein transfer, the
membranes were blocked with 5% non-fat dry milk in
PBS (10mM phosphate buffer pH 7.2, 150 mM NaCl),
incubated with the indicated antibodies: goat polyclonal
anti-Timp1 (R&D), rabbit polyclonal anti-β1-integrin
(Calbiochem), rabbit polyclonal anti-CD63 (Santa Cruz),
rabbit polyclonal anti-phospho Akt (Cell Signaling) and
rabbit polyclonal Akt (Cell Signaling) overnight at 4°C,
and the signal was detected using horseradish peroxid-
ase–conjugated anti–immunoglobulin G antibody (KPL;
Gaithersburg, MD) followed by development using
chemiluminescence substrate (SuperSignal West Pico
Chemiluminescent Substrate; Pierce Chemical, Rockford,
IL).
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Gelatinase activity was determined by zymography, as pre-
viously described [20,21]. In brief, 48 hours conditioned
media (10 μg) were submitted to 10% polyacrilamide gel
electrophoresis with 1% gelatin as substrate (30 mA per
gel, in ice bath). After run, gels were washed four times in
2% Triton X-100, 5 min each, in order to remove SDS and
renaturate enzymes. Gels were then incubated overnight
at 37°C in 50 mM Tris–HCl buffer pH 8.2, containing 5
mM CaCl2 and 0.5 μM ZnCl2 (incubation buffer). Gels
were stained with 0.5% Coomasie Brilliant Blue R-250 in
30% methanol, 10% acetic acid for 30 min, and then prop-
erly destained until clear (degraded) bands could be seen.
Zymograms were scanned with Epson Expression 1680
flatbed scanner (Epson America, Inc., Long Beach, CA,
USA), and densitometric analysis was performed with
TotalLab Quant v11 (TotalLab Ltd., Newcastle, UK). Ex-
periments were always performed in quadruplicates.
Colony formation assay
MaGFP, MaT1S, MP#2, Mel2, Mel3, Mel4, Mel11, Mel
25, Mel33 cells (1×102) were cultured in adherent condi-
tions in complete medium on 6-well plates to allow col-
ony formation. After seven days, colonies were washed
with PBS, fixed in 3.7% (v/v) formaldehyde for 15 mi-
nutes, stained with 1% Toluidine blue 1% Borax for 5
minutes and washed with water. For quantification of
survival cells, the staining was dissolved in 1% SDS and
the absorbance at 570 nm was evaluated using an ELISA
microplate reader.
Flow cytometry analysis
Cultured cells were harvested with trypsin. After trypsin
inactivation, cells were washed with PBS containing 1%
BSA and incubated with anti-CD63 (Santa Cruz) diluted
in 1% BSA in PBS for 1 hour under agitation at 4°C.
After incubation, cells were washed with PBS and incu-
bated with secondary antibody anti-IgG Alexa-488 (Mo-
lecular Probes) for 45 minutes under agitation at room
temperature. After three washes with PBS containing
0.1% BSA, cells were analyzed in a flow cytometer
(FACScalibur, Becton Dickinson).
Co-immunoprecipitation assays
Extracts from murine melan-a, 4C, 4C11- and 4C11+
cell lines and human MP#2, Mel2, Mel3, Mel14 cell lines
were pre-cleared with 50 μl of G protein-coupled to
agarose beads (Gibco BRL, Gaitherburg, MD) for 2
hours at 4°C under agitation. The suspension was
centrifuged at 10.000 rpm for 15 minutes at 4°C and the
collected supernatant was incubated overnight at 4°C
with specific antibodies against CD63 (Santa Cruz), β1-
integrin (Calbiochem) and TIMP1 (Santa Cruz). The
suspension was incubated with G protein-agarose for 4hat 4°C under agitation and centrifuged at 6000 rpm for
10 seconds at 4°C. The beads were collected and washed
three times for 10 minutes at 4°C with wash buffer A
(10 mM Tris pH 8.0, 150 mM NaCl, 0.1% Triton X-100)
and two times with wash buffer B (10 mMTris pH 6.8).
Beads were added to 60 μL of reducing sample buffer,
which were boiled for 5 min, separated by electrophor-
esis on polyacrylamide-SDS 10% and 15%, transferred to
PVDF membrane and incubated with antibodies of
interest.
Conditioned medium
Melan-a and 4C11+ cell lines (1×106) were maintained
in RMPI medium pH 6.9 with 0.5% fetal bovine serum
for 48 hours. After 48 hours, the supernatant was col-
lected and centrifuged at 2000 rpm for 3 minutes and
used in cell survival experiments.
Anoikis resistance assay
This assay was performed in two ways. First, to evaluate
the relative number of surviving cells (adherent and
suspended cells) after deadhesion, MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay was performed. For this, adherent melan-a cells
were harvested by mild trypsin treatment and 1×105
cells were cultured per mL on 1% (w/v) agarose-coated
plates for 96 hours (D96h) in the absence or presence of
melan-a or 4C11+ conditioned medium and in the ab-
sence or presence of 20 μL of Timp1-neutralizing anti-
body (R&D) in fresh medium containing 5% (v/v) FBS.
After 96 h in suspension, cells were collected, trans-
ferred to 96-well plate and incubated with MTT. To en-
sure that all viable cells would be analyzed, the plate
was centrifuged, cells were lysed with isopropanol and
the absorbance at 620 nm was recorded in each well
using an ELISA microplate reader. This experiment was
performed in biological triplicate. Statistical analysis
were made using Student's T test for unpaired samples.
Second, to evaluate the relative number of cells able to
form colonies after submitted to anchorage impedi-
ment, melan-a, 4C11-, 4C11+, MaT1S and MaGFP cells
were cultured in complete medium for 24 hours on 6-
well plates. These cells were harvested by mild trypsin
treatment and 2.5×103 cells per mL were cultured on
1% (w/v) agarose-coated plates for 96 hours (D96h) in
the absence or presence of melan-a or 4C11+ condi-
tioned medium, Timp1 neutralizing antibody (R&D),
0.5 μM Wortmannin, a PI3-K inhibitor, (Calbiochem,
Darmstadt, Germany) or 2.5 μM LY294002, a PI3-K
specific inhibitor (Sigma) in fresh medium containing
0.5% (v/v) FBS at 37°C in 5% CO2. The cells were col-
lected by centrifugation, seeded on 60 mm-dishes and
grown for five days to allow colony formation. Colonies
were washed with PBS, fixed in 3.7% (v/v) formaldehyde
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nutes and washed with water. For quantification of sur-
vival cells, the staining was lysed in 1% SDS and
absorbance at 570 nm was evaluated using an ELISA
microplate reader.Statistical analysis
All tests were conducted in biological triplicate. The re-
sults were organized into a database using the statistical
program GraphPad Prism 5 (GraphPad Software, Inc. -
California, USA). The level of significance utilized was
p<0.05. The statistical tests performed were: Student's
T test for unpaired samples, One-way ANOVA followed by
Tukey's multiple comparison tests and Spearman's Rank
Correlation.Figure 1 Increased association of Timp1 on the cell surface along me
real time PCR. B. Membrane-enriched extracts were separated on 15% poly
membrane was incubated with polyclonal antibody specific to Timp1. The
The supernatants of cell cultures were collected and lyophilized. The prese
Conditioned media (10 μg) from melan-a, 4C, 4C11- and 4C11+ cell lines w
maintained in suspension for 96 hours and viable cells were estimated usin
murine non-tumorigenic melanocyte lineage; 4C: pre-malignant melanocyt
melanoma cells. **p < 0.01, ***p < 0.001, ****p < 0.0001.Results
Increased levels of membrane-bound and secreted Timp1
in cells representing melanoma progression
Previous data from our laboratory have shown signifi-
cant and progressive increase in the expression of timp1
in cells representing different phases of melanoma pro-
gression. This increase was accompanied by anoikis re-
sistance and more aggressive phenotype in vivo [17]. In
agreement with our previous data, a progressive increase
of Timp1 mRNA expression was found in 4C11- and
4C11+ melanoma cell lines (Figure 1A), as described for
other melanoma cell lines from our model [17]. To
analyze the Timp1 protein expression and especially its
association with cell surface, membrane-enriched ex-
tracts of melan-a, 4C, 4C11- and 4C11+ cell lines were
separated by SDS/PAGE. Timp1 protein expression waslanoma progression. A. mRNA levels of Timp1 were determined by
acrylamide gel SDS/PAGE and transferred to a PVDF membrane. The
constitutive expression of β-actin was used as endogenous control. C.
nce of soluble Timp1 was identified by Western Blotting. D.
ere evaluated for MMPs activity. E. The same cell lines were
g MTT. Experiments were always performed in quadruplicates. ma:
es; 4C11-: non-metastatic melanoma cells; 4C11+: metastatic
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from anchorage impediment of melan-a melanocytes
(Figure 1B). Soluble Timp1 was found in the conditioned
media from pre-malignant 4C, and 4C11- and 4C11+
melanoma cell lines, but not in that from non-
tumorigenic melan-a melanocytes (Figure 1C). Although
the most known function of Timp1 is to inhibit matrix
metalloproteinases, no correlation between Timp1 ex-
pression and MMPs activity was observed in our model,
since Timp1-expressing melanoma cells presented high
MMP activity (Figure 1D). Figure 1E shows that cell
lines representing melanoma progression and expressing
high levels of Timp1 present increased capability to form
colonies compared to melan-a melanocytes.
Timp1 associates with β1-integrin and CD63 along melan-
a melanocyte malignant transformation
Based on its importance and well-established role,
β1-integrin expression profile was first investigated in
our model by Western Blot. A differential migration
shift was observed in the bands corresponding to
β1-integrin along melanoma genesis (Figure 2A). Inter-
estingly, metastatic 4C11+ melanoma cell line showed
higher proportion between high (around 120 kDa) and
low molecular mass bands (around 105 kDa) compared
to melan-a melanocytes, pre-malignant 4C cells and
non-metastatic 4C11- melanoma cell line (Figure 2A).
The high molecular mass band corresponds to theFigure 2 A tight Timp1/CD63/β1-integrin complex is formed only in t
in murine melan-a, 4C, 4C11- and 4C11+ cell lines by Western blotting usin
eletrophoretic migration in the metastatic 4C11+ melanoma cell line. The s
endogenous control. B. CD63 protein expression was evaluated by flow cy
extracts from melan-a, 4C, 4C11-, and 4C11+ cell lines were immunoprecip
blotting with anti-Timp1 and anti-β1-integrin. ma: non-tumorigenic melano
melanoma cells; 4C11+: metastatic melanoma cells. *p < 0.05, **p < 0.01.mature and highly glycosylated form of β1-integrin and
its increase in relation to the immature form (low mo-
lecular mass) is in agreement with the literature, since
β1-integrins may present aberrant glycosylation in
tumorigenic cells [22].
CD63 expression, mainly on the cell surface, was eval-
uated in melan-a, 4C, 4C11- and 4C11+ cell lines, by
flow cytometry using a specific polyclonal antibody
against CD63. Higher level of CD63 protein expression
was observed in pre-malignant 4C melanocytes and
non-metastatic 4C11- melanoma cells compared to non-
tumorigenic melan-a melanocytes and metastatic 4C11+
melanoma cells (Figure 2B).
In our melanoma model, both increase in Timp1 ex-
pression and anoikis resistance are acquired along tumor
progression. Once it was shown that in human breast
epithelial cells the interaction among CD63, TIMP1 and
β1-integrin can regulate apoptosis [15], we analyzed the
possible differential interaction among CD63, Timp1
and β1-integrin in cell lines corresponding to different
stages of melanoma progression. For this, the interac-
tions among CD63, Timp1 and β1-integrin proteins on
the surface of melan-a, 4C, 4C11-, and 4C11+ cell lines
were analyzed by protein co-immunoprecipitation assays
using membrane-enriched extracts and specific antibodies
for the molecules of interest. Western blot analysis
performed after immunoprecipitation with anti-β1-
integrin antibody showed interaction between Timp1umorigenic cell lines. A. β1-integrin expression pattern was analyzed
g a specific polyclonal antibody. Note the shift of β1-integrin
ame membrane was reprobed with anti-actin antibody as an
tometry using antibody specific. C. Membrane-enriched protein
itated with anti-CD63 and anti-β1-integrin and analyzed by Western
cytes melan-a; 4C: pre-malignant melanocytes; 4C11-: non-metastatic
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lines (4C11- and 4C11+), but not in non-tumorigenic
melan-a or pre-malignant 4C melanocytes (Figure 2C).
The interaction between Timp1 and CD63 was also
analyzed by immunoprecipitating CD63 complexes
followed by Western blot using an antibody against
Timp1. The interaction between CD63 and Timp1 was
observed in pre-malignant 4C melanocytes and 4C11-
and 4C11+ melanoma cell lines, but not in the parental
melan-a melanocytes (Figure 2C). The analysis of
membrane-enriched extracts immunoprecipitated with
anti-CD63 antibody followed by Western blot using
anti-β1-integrin antibody showed that β1-integrin-CD63
interaction occurs in all lineages, but is more intense
along melanoma progression (4C, 4C11- and 4C11+ cell
lines) (Figure 2C). Data obtained from these co-
immunoprecipitation assays using cell lines representing
different stages of melanocyte malignant transformation
show differential interaction among CD63, Timp1 and
β1-integrin along tumor progression. If the survival sig-
naling triggered by Timp1 depends on its interaction
with molecules such as CD63 and β1-integrin is still
under investigation.Figure 3 The presence of Timp1 in the 4C11+ conditioned medium c
cell lines (2x102) were incubated at 37°C on plates of 60 mm2 adhered to t
visualized by adding the dye toluidine blue in 1% borax. B. The melan-a m
in RPMI pH 6.9 0.5% FCS in the presence of PMA for 48 hours. After this pe
melanocytes were grown in suspension for 96 hours in three different con
conditioned medium, or c) with 4C11+ conditioned medium in the presen
clones by clonogenic assay was analyzed. C. After 96 hours of anchorage b
MTT assay. maGFP: murine non-tumorigenic melanocyte lineage transfecte
melanocyte overexpressing Timp1; ma: non-tumorigenic melan-a melanocyTimp1 enriched medium confers clonogenic capacity and
increased survival to melanocytes
To evaluate the effect of Timp1 overexpression in in vitro
tumor cell traits as colony formation and survival, non-
tumorigenic melan-a melanocytes overexpressing Timp1
(MaT1S) were subjected to colony formation assay. As ob-
served in Figure 3A, Timp1-overexpressing melan-a cells
(MaT1S) revealed larger potential to survive and growth
under low confluence condition, resulting in an increase
colony formation capability than their control, melan-a
cells expressing Green Fluorescent Protein (MaGFP).
Since Timp1 is present in the conditioned media of pre-
malignant 4C melanocytes and 4C11- and 4C11+ melan-
oma cells, but not in melan-a melanocyte, and it interacts
with proteins expressed on the cell surface, such as CD63
and β1-integrin, the next step was to analyze the ability of
soluble Timp1 to confer anoikis resistance to melan-a
cells. For this, two different approaches were done with
melan-a melanocytes in the presence of conditioned
medium from melan-a or 4C11+ cultures: the clonogenic
(Figure 3B) and MTT (Figure 3C) assays after maintaining
melan-a melanocytes in suspension for 96 hours. It was
observed that in the presence of conditioned mediumonfers anoikis resistance to melanocytes. A. The MaGFP and MaT1S
he substrate for 7 days. After this period, the formation of clones was
elanocytes and 4C11+ melanoma cell lines were maintained in culture
riod, the medium conditioned by these cells was collected. Melan-a
ditions: a) with melan-a conditioned medium, b) with 4C11+
ce of Timp1-neutralizing antibody. After 96 hours, the formation of
lockage, all cells were collected and viable cells were determined by
d with fluorescent protein GFP; maT1S: murine non-tumorigenic
tes; 4C11+: metastatic melanoma cells. **p < 0.01, ***p < 0.001.
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http://www.molecular-cancer.com/content/12/1/22from 4C11+ melanoma cells, melan-a cells became more
clonogenic than in the presence of their own conditioned
medium (Figure 3B). Furthermore, the neutralization of
Timp1 with a specific antibody reversed the acquisition of
anoikis-resistant phenotype by melan-a cells in the pres-
ence of conditioned medium from 4C11+ melanoma cells
(Figure 3B). The same was observed in MTT assay, in
which 4C11+ conditioned medium conferred survival
advantages to melan-a melanocytes during anchorage
blockade and this was reversed in the presence of a
Timp1-neutralizing antibody (Figure 3C). It is important
to note that in this assay, all viable cells, not only adherent
ones, are detected. These data indicate that exogenous
soluble Timp1 confers resistance to anoikis to melan-a
melanocytes.
Timp1 overexpression activates PI3-K signaling pathway
in melanocytes
As previously mentioned, several studies indicate that
TIMP1 mediates activation of specific signal trans-Figure 4 PI3-K signaling pathway is involved in anoikis resistance phe
treated overnight with PI3-K inhibitors, Wortmannin (A) or LY294002 (B), an
stably transfected with GFP (control transfection, MaGFP) and Timp1 (MaT1
activation was assessed by Western blotting. *p < 0.05, **p < 0.01, ****p < 0duction pathways that protect cells from apoptosis in a
manner that is independent of its metalloproteinase in-
hibitory activity [15,18]. We observed that melan-a cells
that overexpress Timp1 (maT1S) were less anoikis resist-
ant in the presence of Wortmannin (Figure 4A) or
LY294002 (Figure 4B), indicating the involvement of
PI3-K signaling pathway in this process. One of the
downstream targets of PI3-K is AKT phosphorylation
[18]. To investigate if Akt activation was involved in
anoikis resistance conferred by Timp1, adherent (D0)
and deadherent (D1h, D3h, D5h, D24h) MaT1S and
MaGFP cells were assayed for the levels of activated Akt.
Figure 4C shows that Akt is phosphorylated in melano-
cytes subjected to anchorage impediment; however,
Timp1 overexpression did not contribute to its
activation, since there was no difference between phos-
phorylated Akt levels in MaGFP and MaT1S cells. Our
results suggest that soluble Timp1 mediates activation of
PI3-K signal transduction pathways in melanocytes
subjected to anchorage blockade, contributing to anoikisnotype conferred by Timp1. The MaGFP and MaT1S cell lines were
d their clonogenic capability was evaluated. C. Melan-a melanocytes
S) were maintained in suspension for 1, 3, 5 and 24 hours. The Akt
.0001.
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http://www.molecular-cancer.com/content/12/1/22resistance, but this regulation is independent of Akt
phosphorylation.
Neutralizing Timp1 reverses anoikis-resistant phenotype
in melanoma cells
As previously shown, Timp1-rich conditioned medium
from 4C11+ culture confers anoikis resistance to melan-
a melanocytes. In order to check if Timp1 also confers
anoikis-resistance in melanoma cells, non-metastatic
4C11- and metastatic 4C11+ melanoma cells were
subjected to anchorage blockade for 96 hours in the
presence or not of a Timp1-neutralizing antibody. As
shown in Figure 5, neutralizing Timp1 renders both
non-metastatic (A) and metastatic (B) cell lines more
sensitive to anoikis.
PI3-K inhibition abrogates survival in melanoma cells
To examine whether the PI3-K signaling pathway is in-
volved in anoikis resistance conferred by soluble Timp1,
non-metastatic 4C11- and metastatic 4C11+ melanomaFigure 5 Timp1 neutralization renders melanoma cells sensitive to an
cell lines were maintained in suspension for 96 hours in the presence or ab
were plated and after 5 days clonogenic capacity was analyzed. 4C11-: non
NT: non-treated; nTimp1: Timp1-neutralizing antibody. ****p < 0.0001.cells were maintained in suspension for 96 hours in the
presence or not of Wortmannin or LY294002. After this,
cells were collected and anoikis resistance was analyzed.
Figure 6 shows that both Wortmannin and LY294002
sensitized non-metastatic 4C11- (A and B, respectively)
and metastatic 4C11+ (C and D, respectively) melanoma
cells to anoikis. These data suggest that PI3- signaling
pathway activation confers anoikis resistance to melan-
oma cells that overexpress Timp1.
TIMP1 is superexpressed and associated with β1-integrins
in human metastatic melanoma cells, but not in primary
human melanocytes
TIMP1 levels are increased in cancer patients, particu-
larly in those with breast or colorectal carcinoma, and
this augment is negatively associated with patient out-
come [23]. Recent studies have suggested the clinical
utility of TIMP1 as a biomarker and independent
prognostic factor in breast, colorectal and several
hematological cancers. They are consistent with theoikis. Non-metastatic 4C11- (A) and metastatic 4C11+ (B) melanoma
sence of Timp1-neutralizing antibody. After 96 hours, suspended cells
-metastatic melanoma cells; 4C11+: metastatic melanoma cells;
Figure 6 PI3-K inhibition renders melanoma cells anoikis sensitive. The 4C11- and 4C11+ melanoma cell lines were maintained in
suspension for 96 hours in the presence of Wortmannin (A and B, respectively) or LY294002 (C and D, respectively). After 96 hours, suspended
cells were plated and after 5 days clonogenic capacity was analyzed. 4C11-: non-metastatic melanoma cells; 4C11+: metastatic melanoma cells;
NT: non-treated; Wn: Wortmannin; LY: LY294002. *p < 0.05, **p < 0.01, ***p < 0.001.
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integrins binding. Increased transcript level of Timp1
and CD63 was shown in different human metastatic
melanoma cell lines compared to primary human me-
lanocytes (Figure 7, A and B). Five from seven meta-
static melanoma cells expressed significantly higher
levels of TIMP1 (Figure 7A), and three from seven
melanoma cell lines presented increased levels of
CD63 (Figure 7B) compared to primary human mela-
nocytes. All of six metastatic melanoma cell lines an-
alyzed showed increased expression of β1-integrins
(Figure 7C), and all cell lines, except Mel14,
presented increased ratio between high and low mo-
lecular mass β1-integrin. The association between β1-
integrins and TIMP1 was observed in the human
metastatic melanoma cells, but not in primary mela-
nocytes (Figure 7D). All metastatic melanoma cell
lines studied have more colony formation capacity
when compared to primary melanocytes (Figure 7E).
Interestingly, we found a moderate correlation be-
tween the expression levels of TIMP1 and CD63 and
ability to form colonies (Figure 7G and 7H, respect-
ively). A strong correlation was found between the
expression of TIMP1 and CD63 (Figure 7I) and, when
these two variables were combined in a factor, they
strongly correlate with colony formation capacity
(Figure 7J), reinforcing the possible role of TIMP1,
mainly when associated with increased expression of
CD63, in melanoma genesis.Discussion
Previous data from our laboratory showed a significant
increase in Timp1 expression along melanocyte malig-
nant transformation, in parallel with the acquisition of
an anoikis-resistant phenotype [17]. Increasing Timp1
expression rendered melanoma cell more anoikis-resist-
ant and more efficient in metastases development,
indicating the correlation between Timp1 and poor
prognosis in melanoma [17]. Indeed, different studies
have correlated increased TIMP1 expression with malig-
nant progression and poor prognosis, both in human tu-
mors and murine experimental models [12,24,25]. It has
been commonly shown that TIMP1 is involved in the
regulation of proliferation, cell survival, and differen-
tiation of numerous cell types [26,27], angiogenesis
[28,29] and apoptosis [13,30] through mechanisms ap-
parently independent of MMPs. In this regard, Liu and
colleagues showed that TIMP1 expression protects
breast epithelial cells and human lymphocytes to differ-
ent stimuli that induce apoptosis [31]. In addition,
Kluger and colleagues identified TIMP1 as a plasma
marker in patients with metastatic melanoma [32].
Melanocytes overexpressing Timp1 acquired anoikis-
resistant phenotype [17] and showed more colony for-
mation capability than control MaGFP (Figure 3A),
reinforcing that Timp1 can regulate cell survival in me-
lanocytes. TIMP1 functions are determined depending
on its level and localization (soluble vs. pericellular).
TIMP1 is a secreted protein and may associate with cell
Figure 7 Increased levels of TIMP1, CD63 and β1-integrins in melanoma cells compared to primary melanocytes and association
between Timp1 and β1- integrins only in human metastatic melanoma cells. mRNA levels of TIMP1 and CD63 were measured by real time
PCR (A and B, respectively). C. β1-integrin expression was analyzed in primary human melanocytes MP#2 and human metastatic melanoma cell
lines (Mel2, Mel3, Mel4, Mel14, Mel25 and Mel28) by Western blotting using a specific polyclonal antibody. The same membrane was reprobed
with anti-PCNA antibody as an internal control. D. Membrane-enriched protein extracts from MP#2, Mel2, Mel3 and Mel14 cell lines were
immunoprecipitated with anti-TIMP1 and analyzed by Western blotting with anti-β1-integrin. E and F. Primary human MP#2 melanocytes and
human metastatic melanomas Mel2, Mel3, Mel4, Mel11, Mel25, Mel28 and Mel33 (2x102) were incubated at 37°C on 60 mm plates and colony
formation capacity was determined after 5 days. Spearman’s correlation (r) was used to correlate TIMP1 and clonogenic capacity (G), CD63
expression and clonogenic capacity (H), TIMP1 and CD63 expression (I), and combined TIMP1 and CD63 expression and clonogenic capacity (J).
All analyses were performed using SPSS (v 18, Chicago, IL, USA). The significance level was set at 0.05.
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where it can interact with its partners and mediate cellu-
lar processes [15,23]. In our model, Timp1 was found in
conditioned medium from all cell lines corresponding to
different steps of melanoma progression (4C, 4C11- and
4C11+), except in melan-a melanocytes (Figure 1C).
Although timp1 transcript is increased in metastatic
4C11+ melanoma cell line compared to pre-malignant
4C and non-metastatic 4C11- melanoma cell line
(Figure 1A) and Timp1 protein is augmented at cell sur-
face since pre-malignant 4C to metastatic 4C11+ cell line
(Figure 1B), its presence in the supernatant is more ex-
pressive in pre-malignant 4C and non-metastatic 4C11-
cells compared to melan-a melanocytes (Figure 1C). The
explanation of this discrepancy is still under investigation.
Despite the increase in Timp1 expression in 4C11- and
4C11+ melanoma cell lines, high MMP activity was found
in these melanoma cell lines (Figure 1D), suggesting
MMP-independent functions of Timp1. Recently, Kim
and coworkers showed that colon cancer cells have
TIMP1 molecule bearing aberrant glycosylation, whichimpairs its efficient function as MMP inhibitor [33]. In
fact, an increase in N-linked oligosaccharides was ob-
served in melanoma cells derived from melan-a subjected
to sequential cycles of deadhesion [10], reinforcing the
idea that TIMP1 would confer tumor aggressiveness inde-
pendent of its function on MMP activity. Several studies
have shown changes in the expression pattern of integrins
in different malignant tumors [34,35]. Besides that, alter-
ations in integrin distribution on cell surface and in post-
translational modifications were also observed in many
tumor types [35].
Several authors showed association between TIMPs and
integrins [15,36]. Binding studies have shown that TIMP2
interacts with α3β1 integrin on the cell surface in human
endothelial cells [37]. Interaction between TIMP1 and
αvβ3 confers protection against apoptosis induced by
TNF-α In human osteosarcoma cell lines [37].
Tetraspanins were also described as binding partners for
TIMPs [37]. Tetraspanin family members, including
CD63, CD82 and CD151, also interact with adhesion mol-
ecules, as integrins, and modulate transduction pathways
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are reports indicating that CD63 can regulate both posi-
tively and negatively integrin activity [38]. Several studies
reported alteration in CD63 expression along melanoma
progression [2,39,40]. In our study, the presence of CD63
protein was observed in all cell lines, especially in non-
metastatic 4C11- melanoma cells (Figure 2B). This result
is in agreement with published data that showed increased
CD63 expression mainly in early stages of melanoma [41].
Furthermore, metastatic 4C11+ melanoma cells present
decreased CD63 expression compared to non-metastatic
4C11-melanoma cells (Figure 2B), corroborating the data
showing that inhibition of CD63 expression increased cell
motility, matrix degrading activity and invasiveness of
melanoma cells in vitro [42]. Recently, CD63 protein was
detected in human breast epithelial cells as a binding part-
ner of TIMP1 on cell surface [15]. These authors con-
firmed by immunoprecipitation and confocal microscopy
the co-localization of CD63 and TIMP1 with β1-integrin
and showed that reduced levels of CD63 by shRNA
resulted in reduced binding of TIMP1 to cell surface,
β1-integrin activation and cell survival signaling of breast
epithelial cells. Other authors have also shown that CD63
regulates some signaling pathways involved in anti-
apoptotic activity of TIMP1 [43].
In our model, CD63 is interacting with Timp1 in pre-
malignant 4C melanocytes and in tumorigenic cell lines
(Figure 2C), cells that acquire an anoikis-resistant
phenotype (Figure 1E). In these cells, CD63 may be
recruiting signaling molecules responsible for the
increase in cell survival, since the short cytoplasmic tail
of CD63 interacts with signaling molecules including
phosIphatidylinositol 4-kinase (PI4-K) and Src [44-47] and
regulates signaling pathways involving proteins such asFigure 8 Hypothesis for the assembly of CD63/β1-integrins/Timp1 co
association between CD63 and β1-integrins occurs in melan-a melanocytes
these molecules in pre-malignant 4C melanocytes and 4C11- and 4C11+ m
complex and acquisition of anoikis-resistant phenotype. The absence of ph
less efficient survival transduction pathway, differently of what is seen in m
tightly assembled.FAK, Gab2, PI3-K and Akt [48-50]. However, we did not
observe interaction between β1-integrin and Timp1 in
pre-malignant 4C cell line. Timp1 was shown to interact
with β1-integrins only in 4C11- and 4C11+ melanoma
cells (Figure 2C). Therefore, it is possible to suggest that,
in this model, the tight complex comprised by Timp1,
CD63 and β1-integrins contributes to the acquisition
of malignant phenotype, since the interaction among these
three molecules was observed only in melanoma
cell lines (Figure 8). Preventing adhesion to the substrate
could result in changes in the structure and composi-
tion of lipid rafts, glycosphingolipid-cholesterol-enriched
microdomains, affecting Timp1/CD63/β1-integrin com-
plex assembly along melanoma development. The CD63
tetraspanin and β1-integrin may be found in lipid rafts,
where CD63 can recruit signaling proteins [48]. Further-
more, alterations in integrin conformation control their
capability to bind to ligands [49]. However, it has been
demonstrated that a significant proportion of complexes
containing integrins and tetraspanins are compartmental-
ized out of lipids rafts [50-52]. It is also possible that
integrin-tetraspanin complexes shuttle in and out of rafts
and thereby control the recruitment of different proteins
into these compartments, consequently modulating signal-
ing events in many ways [50]. In this way, the se-
quential cycles of anchorage blockade may alter this
compartmentalization and lead to alterations in signaling
pathways, resulting in malignant transformation. Next, we
evaluated the impact of secreted Timp1 on melanocytes
cell survival. As shown in Figure 3B and C, non-
tumorigenic melan-a melanocytes maintained in suspen-
sion for 96 hours in the presence of conditioned medium
from 4C11+ melanoma cells were more anoikis-resistant
than those maintained in the presence of conditionedmplex along melanoma genesis. In the absence of Timp1, almost no
, which might contribute to their anoikis sensitivity. The presence of
elanoma cells result in the formation of CD63/β1-integrins/Timp1
ysical interaction between Timp1 and β1-integrins might result in a
elanoma cell lines, in which this complex seems to be more
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anoikis resistance conferred by conditioned medium from
4C11+ melanoma cells was abrogated by the presence of
Timp1-neutralizing antibody, demonstrating that extracel-
lular Timp1 is important to render melan-a melanocytes
anoikis-resistant.
Interaction between Timp1 and CD63 might activate sur-
vival signaling pathways mediated by β1-integrins, includ-
ing FAK and Src, resulting in PI3-K signaling pathway
activation [15,46]. In our model, the use of PI3-K signaling
pathway inhibitors sensitized Timp1-overexpressing mela-
nocytes to anoikis (Figure 4A and B), suggesting the in-
volvement of PI3-K signal transduction in regulation of cell
survival by Timp1. However, Timp1 did not change Akt ac-
tivation, since melan-a cells overexpressing Timp1 showed
the same levels f phospho-Akt compared to control melan-
a cells (Figure 4C). Indeed, recent studies have shown that
PI3-K signaling pathway can act independently of AKT
phosphorylation, by activating PDK1, which in turn acti-
vates other proteins such as PKC [53,54]. It is possible that
PKC is constitutively activated in melanoma cells since
their survival is PMA independent [10]. Moreover, both
PI3-K inhibitor and Timp1-neutralizing antibody decreased
anoikis resistance of melanoma cells (Figure 6), suggesting
that also in tumorigenic cells survival modulation by Timp1
is regulated by PI3-K signaling pathway.
Several studies pointed TIMP1 as a promising tumor
biomarker, since it has been found in high levels in the
plasma of patients bearing different types of cancer.
Clinical studies using primary breast tumors, for ex-
ample, have shown an association between high levels of
TIMP1 mRNA and protein and poor prognosis in pa-
tients with breast cancer [55,56]. Moreover, high levels
of TIMP1 in tumor tissue are strongly associated with
poor response to chemotherapy [57,58]. In addition, we
observed high levels of TIMP1 in five from seven meta-
static human melanoma cell lines analyzed (Figure 7A).
Both TIMP1 and CD63 levels correlated with colony for-
mation capacity (Figure 7G and H). A strong and signifi-
cant correlation was found between TIMP1 and CD63
levels (Figure 7I) and, more interestingly, TIMP1 and
CD63 expression combined in a factor strongly corre-
lates to colony formation ability (Figure 7J), pointing
TIMP1, mainly when associated with increased CD63
expression, as a potential biomarker of melanoma.
The absence of CD63/β1-integrins/Timp1 complex
formation in the parental non-tumorigenic melan-a
melanocytes may be the responsible for the lack of a sur-
vival signaling to prevent anoikis. In the case of cell line
corresponding to pre-malignant melanocytes (4C), interac-
tions between CD63/β1-integrins and CD63/Timp1 were
observed, which could initiate PI3-K signaling pathway for
cell survival, since the 4C cell line is more resistant to
anoikis when compared with its parental lineage, melan-a.CD63/β1-integrins, CD63/Timp1 and Timp1/β1-integrins
interactions were detected in the tumorigenic 4C11- and
4C11+ cell lines, suggesting that CD63/β1-integrins/
Timp1 form a tighter complex when compared to that
in pre-malignant melanocytes (4C), which could result
in more efficient activation of PI3-K signaling pathway
and in melanoma development (Figure 8), indicating the
relevance of supramolecular complex formation in tumor
progression.
In conclusion, our data demonstrate differential inter-
action among CD63, Timp1 and β1-integrins between
normal and melanoma cells and that this binding may
regulate essential processes for tumorigenesis such as
anoikis resistance. These findings provide evidences that
the supramolecular complex containing Timp1, CD63
and β1- integrin triggers PI3-K signaling pathway that
contribute to melanoma progression through apoptosis
inhibition (Figure 8). A better understanding of how
Timp1 modulates anoikis resistance during the melan-
oma progression may be valuable in developing new
therapeutic interventions.
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